

# Nathan, James Brendish

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6983825/publications.pdf>

Version: 2024-02-01

29  
papers

1,013  
citations

566801

15  
h-index

580395

25  
g-index

30  
all docs

30  
docs citations

30  
times ranked

1578  
citing authors

#	ARTICLE	IF	CITATIONS
1	A SARS-CoV-2 nucleocapsid ELISA represents a low-cost alternative to lateral flow testing for community screening in LMI countries. <i>Journal of Infection</i> , 2022, 84, 48-55.	1.7	7
2	FebriDx host response point-of-care testing improves patient triage for coronavirus disease 2019 (COVID-19) in the emergency department. <i>Infection Control and Hospital Epidemiology</i> , 2022, 43, 979-986.	1.0	8
3	Routine molecular point-of-care testing for SARS-CoV-2 reduces hospital-acquired COVID-19. <i>Journal of Infection</i> , 2022, 84, 558-565.	1.7	9
4	FebriDx host response point-of-care testing improves patient triage for coronavirus disease 2019 (COVID-19) in the emergency department – ADDENDUM. <i>Infection Control and Hospital Epidemiology</i> , 2022, , 1-1.	1.0	0
5	Combined RT-PCR and Host Response Point-of-Care Testing in Patients Hospitalised with Suspected COVID-19: A Prospective Diagnostic Accuracy Study. <i>Infectious Diseases and Therapy</i> , 2022, 11, 1267-1280.	1.8	3
6	Clinical impact of a routine, molecular, point-of-care, test-and-treat strategy for influenza in adults admitted to hospital (FluPOC): a multicentre, open-label, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 419-429.	5.2	22
7	Influenza vaccination: protecting the most vulnerable. <i>European Respiratory Review</i> , 2021, 30, 200258.	3.0	30
8	Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination. <i>Med</i> , 2021, 2, 701-719.e19.	2.2	73
9	Neuraminidase inhibitor use in adults presenting to hospital with suspected influenza: A questionnaire-based survey of practice among hospital physicians. <i>Clinical Infection in Practice</i> , 2021, 11, 100075.	0.2	1
10	Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial. <i>Frontiers in Immunology</i> , 2021, 12, 694759.	2.2	22
11	SARS-CoV-2 viral load at presentation to hospital is independently associated with the risk of death. <i>Journal of Infection</i> , 2021, 83, 458-466.	1.7	11
12	Increase in circulation of non-SARS-CoV-2 respiratory viruses following easing of social distancing is associated with increasing hospital attendance. <i>Journal of Infection</i> , 2021, 83, 496-522.	1.7	0
13	Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study. <i>Lancet Respiratory Medicine</i> , 2020, 8, 1192-1200.	5.2	99
14	SARS-CoV-2 has displaced other seasonal respiratory viruses: Results from a prospective cohort study. <i>Journal of Infection</i> , 2020, 81, 966-972.	1.7	65
15	Physical distancing in schools for SARS-CoV-2 and the resurgence of rhinovirus. <i>Lancet Respiratory Medicine</i> , 2020, 8, e92-e93.	5.2	92
16	Diagnostic accuracy of the FebriDx host response point-of-care test in patients hospitalised with suspected COVID-19. <i>Journal of Infection</i> , 2020, 81, 607-613.	1.7	30
17	Clinical characteristics, symptoms and outcomes of 1054 adults presenting to hospital with suspected COVID-19: A comparison of patients with and without SARS-CoV-2 infection. <i>Journal of Infection</i> , 2020, 81, 937-943.	1.7	29
18	Impact of point-of-care testing for respiratory viruses on antibiotic use in adults with exacerbation of airways disease. <i>Journal of Infection</i> , 2019, 79, 357-362.	1.7	16

#	ARTICLE	IF	CITATIONS
19	Hospitalised adults with pneumonia are frequently misclassified as another diagnosis. <i>Respiratory Medicine</i> , 2019, 150, 81-84.	1.3	7
20	Molecular Point-of-care Testing for Influenza to Improve Early Neuraminidase Inhibitor Treatment and Outcomes in Hospitalized Adults. <i>Clinical Infectious Diseases</i> , 2019, 68, 2154-2155.	2.9	2
21	Impact of turnaround time on outcome with point-of-care testing for respiratory viruses: a <i>post hoc</i> analysis from a randomised controlled trial. <i>European Respiratory Journal</i> , 2018, 52, 1800555.	3.1	34
22	Molecular point-of-care testing for respiratory viruses versus routine clinical care in adults with acute respiratory illness presenting to secondary care: a pragmatic randomised controlled trial protocol (ResPOC). <i>BMC Infectious Diseases</i> , 2017, 17, 128.	1.3	26
23	Routine molecular point-of-care testing for respiratory viruses in adults presenting to hospital with acute respiratory illness (ResPOC): a pragmatic, open-label, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2017, 5, 401-411.	5.2	230
24	Antiviral treatment of severe non-influenza respiratory virus infection. <i>Current Opinion in Infectious Diseases</i> , 2017, 30, 573-578.	1.3	26
25	Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. <i>JCI Insight</i> , 2017, 2, .	2.3	109
26	Global extent of chloroquine-resistant <i>Plasmodium vivax</i> . <i>Lancet Infectious Diseases</i> , 2015, 15, 630.	4.6	0
27	Point-of-care testing for respiratory viruses in adults: The current landscape and future potential. <i>Journal of Infection</i> , 2015, 71, 501-510.	1.7	61
28	Phase I studies: the role of publicly funded academic-healthcare partnerships. <i>BMJ</i> , 2015, 351, h3889.	3.0	0
29	Respiratory tract infection associated with seizures. <i>BMJ</i> , 2015, 351, h4659.	3.0	1